Actoplus met XR recall
Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, Distributed by: Takeda Pharmaceuticals America, Inc, Deerfield, IL 60015. NDC: 64764-510-30
Why was Actoplus met XR recalled?
Defective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes on the metformin core of the Actoplus met XR tablets.
What should I do if I have this product?
Review the official FDA enforcement record for current instructions.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.
Which lot codes, UPCs or models are affected?
Lot, expiry: A26004, exp Apr 2020; A26443 and A26444, exp Sep 2020
- Product
- Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, Distributed by: Takeda Pharmaceuticals America, Inc, Deerfield, IL 60015. NDC: 64764-510-30
- Recalling firm
- Takeda Development Center Americas, Inc.
- Quantity
- 7,248 bottles
- Distribution
- AR, LA, MS, NC, NJ, OH, PA, SC and Puerto Rico
- Recall date
- October 17, 2018
- Classification
- Class II
- Status
- Terminated
- Agency
- FDA (drug)